Press releaseGlobe Newswire
AIM ImmunoTech
AIM · NYSE American
$0.1662+$0.0031 (+1.90%)TodayMarket closed ·
Prev close $0.1631
Latest news
- Press releaseGlobe Newswire
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential
- Press releaseGlobe Newswire
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
- Press releaseGlobe Newswire
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
- Press releaseGlobe Newswire
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
- Press releaseGlobe Newswire
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
- Press releaseGlobe Newswire
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
- Press releaseGlobe Newswire
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
- Press releaseGlobe Newswire
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
- Press releaseGlobe Newswire
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
Earnings Scheduled For May 13, 2026
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Nasdaq Jumps 200 Points; US Adds 115,000 Jobs In April
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Crude Oil Moves Higher; Jabil Shares Slide After Q2 Results
- Press releaseGlobe Newswire
Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum
- NewsAvi Kapoor
Dow Falls Over 150 POints; US Producer Prices Increase In February
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Nasdaq Dips 200 Points; Alphabet Posts Upbeat Earnings
- News
AIM ImmunoTech Shares Halted, News Pending
- News
AIM ImmunoTech Declares 1-For-1,000 Stock Dividend For Shareholders And Option/Warrant Holders
- Press releaseGlobe Newswire
AIM ImmunoTech Announces Stock Dividend
- Press releasePRNewswire
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views
- NewsAvi Kapoor
US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Crude Oil Gains 2%; CEA Industries Shares Spike Higher
- NewsAvi Kapoor
US Stocks Mixed; Enterprise Products Partners Posts Upbeat Earnings
- NewsAvi Kapoor
Dow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March
- Press releaseBusiness Wire
AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting
- Press releaseBusiness Wire
AIM ImmunoTech Reminds Shareholders to Vote "FOR" All Four Incumbent Board Members on the WHITE Universal Proxy Card
- Press releaseBusiness Wire
AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members
- Press releaseGlobe Newswire
AIM's Clinical Strategy Under Incumbent Board Has Totally Failed
- Press releaseBusiness Wire
Glass Lewis Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell
- Press releaseGlobe Newswire
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card
- Press releaseBusiness Wire
ISS Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan and Dr. William M. Mitchell
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.